相关实验视频
Updated: Jul 24, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
纳FLD的药物治疗:基于代谢干预的更新机会
Yaodi Shao1, Suzhen Chen1, Liu Han2
1Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
非酒精性脂肪肝 (NAFLD) 是与代谢功能障碍相关的日益严重的健康问题. 准代谢途径为NAFLD药物开发提供了有希望的治疗策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 是一种普遍存在的慢性肝病,其范围从肥胖症到肝硬化.
- NAFLD与癌症和心血管疾病的死亡风险增加有关.
- 缺乏FDA批准的药物治疗方法凸显了一个尚未满足的医疗需求.
研究的目的:
- 总结了促进NAFLD病变的代谢特征.
- 在葡萄糖,脂质和肠道新陈代谢中识别潜在的药理目标.
- 审查NAFLD代谢干预药物治疗的全球进展.
主要方法:
- 在NAFLD中代谢变化的文献综述.
- 对代谢干预的临床研究的分析.
- 综合目前关于NAFLD药物开发的研究.
主要成果:
- NAFLD的发病因子与系统代谢功能障碍密切相关.
- 相互连接的代谢途径 (葡萄糖,脂质,肠道) 是关键的.
- 代谢干预显示了新型NAFLD药物开发的潜力.
结论:
- 针对相互连接的代谢途径是NAFLD的一个有希望的策略.
- 了解NAFLD的代谢基础可以指导新的药物治疗开发.
- 对代谢干预的进一步研究可能会产生有效的NAFLD治疗方法.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
相关概念视频
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Peripheral Artery Disease III: Interprofessional Care
Heart Failure V: Medical Management
Alzheimer's Disease: Treatment
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...